In this video, health-care analyst David Williamson discusses two cutting-edge but very different hepatitis C drug candidates under FDA review. A little less than a month ago, Johnson & Johnson received priority status for its simeprevir, shortening its decision time by four months.
Investors recently learned that Gilead also received priority status for its entry sofosbuvir. Watch and find out why Gilead is set to change the entire treatment paradigm for this disease and why approval for Gilead may be a boost for J&J.
The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. It recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.